Other experimental potential biomarkers that are being tested in patients with hematologic malignancies are high-sensitivity CRP (Hs-CRP), interleukin-6 (IL-6), myeloperoxidase (MPO), fatty-acid-binding protein (FABP), glycogen-phosphorylase-binding protein (GPBP) and neuregulin-1 (NRG-1). Here, IL6 is linked to hematologic disorder.